<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS: To explore <z:chebi fb="105" ids="17234">glucose</z:chebi> lowering response to insulin initiation or switch to insulin glargine in <z:mp ids='MP_0001261'>obese</z:mp> and non-<z:mp ids='MP_0001261'>obese</z:mp> individuals with type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> (T2DM) and to examine <z:mp ids='MP_0005456'>weight gain</z:mp> and <z:e sem="disease" ids="C0745153" disease_type="Disease or Syndrome" abbrv="">hypoglycaemic episodes</z:e> in this group </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: Post hoc subgroup analysis using data of <z:mp ids='MP_0001261'>obese</z:mp> and non-<z:mp ids='MP_0001261'>obese</z:mp> participants from a large multi-centre (4555 participants with T2DM), multi-national 24-week randomized controlled trial of investigator titrated insulin glargine versus patient self-managed titrated insulin glargine </plain></SENT>
<SENT sid="2" pm="."><plain>This analysis was carried out to compare two subgroups: <z:mp ids='MP_0001261'>obese</z:mp> (&gt; or =30 kg/m2) and non-<z:mp ids='MP_0001261'>obese</z:mp> (&lt;30 kg/m2) participants </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: The mean body mass index (BMI) values were 33.7 kg/m2(n = 1833) and 25.9 kg/m(2)(n = 2755) in <z:mp ids='MP_0001261'>obese</z:mp> and non-<z:mp ids='MP_0001261'>obese</z:mp> subjects, respectively </plain></SENT>
<SENT sid="4" pm="."><plain>There was a significant reduction in glycated <z:chebi fb="34" ids="35143">haemoglobin</z:chebi> (HbA1c) from baseline in both subgroups but no significant difference between subgroups (1.15 vs. 1.15%, p = 0.50) </plain></SENT>
<SENT sid="5" pm="."><plain>Overall, there was a 1.21 kg (s.d </plain></SENT>
<SENT sid="6" pm="."><plain>3.3) increase in weight in individuals who were non-<z:mp ids='MP_0001261'>obese</z:mp> and a 1.08 kg (s.d </plain></SENT>
<SENT sid="7" pm="."><plain>3.9) increase in <z:mp ids='MP_0001261'>obese</z:mp> individuals (p = 0.67) </plain></SENT>
<SENT sid="8" pm="."><plain>There was no significant difference in the proportion of participants achieving an HbA1c of &lt;7.0% at 6 months in both the subgroups (28.8 vs. 27.1%, p = 0.20) </plain></SENT>
<SENT sid="9" pm="."><plain>In multiple logistic regression, BMI was not a prognostic factor in achieving a target of HbA1c &lt; or = 7.0% </plain></SENT>
<SENT sid="10" pm="."><plain>There was no significant difference in severe <z:e sem="disease" ids="C0745153" disease_type="Disease or Syndrome" abbrv="">hypoglycaemic episodes</z:e> between <z:mp ids='MP_0001261'>obese</z:mp> and non-<z:mp ids='MP_0001261'>obese</z:mp> subgroups (1.3 vs. 1.0%); however, significantly more non-<z:mp ids='MP_0001261'>obese</z:mp> individuals experienced nocturnal <z:e sem="disease" ids="C0745153" disease_type="Disease or Syndrome" abbrv="">hypoglycaemic episodes</z:e>(4.5 vs. 2.4%, p &lt; 0.05) </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: In this study, treatment with insulin glargine in people with T2DM was associated with a significant reduction in HbA1c without differential increase in <z:mp ids='MP_0005456'>weight gain</z:mp> in <z:mp ids='MP_0001261'>obese</z:mp> and non-<z:mp ids='MP_0001261'>obese</z:mp> subgroups </plain></SENT>
<SENT sid="12" pm="."><plain>Rates of severe <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> were not different between <z:mp ids='MP_0001261'>obese</z:mp> and non-<z:mp ids='MP_0001261'>obese</z:mp> subgroups </plain></SENT>
</text></document>